Mineralys Therapeutics (MLYS) Total Current Liabilities (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Total Current Liabilities data on file, last reported at $14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 9.95% year-over-year to $14.7 million; the trailing twelve-month figure through Mar 2026 stood at $14.7 million (up 9.95% YoY), and the FY2025 full-year result was $15.1 million, up 3.19% from the prior year.
• Total Current Liabilities declined to $14.7 million in Q1 2026, from $15.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $31.3 million in Q3 2024 to a low of $6.2 million in Q2 2023.
• A 5-year average of $16.5 million and a median of $14.7 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 357.5% in 2024 and sank 30.3% in 2025, its largest moves.
• Tracing MLYS's Total Current Liabilities over 5 years: stood at $8.1 million in 2022, then increased by 29.94% to $10.5 million in 2023, then surged by 39.73% to $14.6 million in 2024, then rose by 3.19% to $15.1 million in 2025, then fell by 2.61% to $14.7 million in 2026.
• Business Quant data shows MLYS's Total Current Liabilities at $14.7 million in Q1 2026, $15.1 million in Q4 2025, and $23.5 million in Q3 2025.